Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy

Panagiotis Gouveris1, Dionysia N Zouki1, Evangelos G Sarris1

  • 1Second Department of Medical Oncology, Agios Savvas Cancer Hospital, Athens, Greece.

Insights

Sarcoidosis can mimic melanoma metastasis, even in patients receiving BRAF/MEK inhibitors or no treatment. Biopsies are crucial to differentiate sarcoidosis from metastatic disease before initiating cancer therapy.

Area of Science:

  • Oncology
  • Pulmonology
  • Dermatology

Background:

  • Sarcoidosis is an inflammatory condition associated with various solid tumors, notably malignant melanoma.
  • Melanoma patients may develop sarcoidosis either spontaneously or secondary to treatments like immunotherapy or targeted therapy.

Observation:

  • This report details two asymptomatic patients with malignant melanoma who presented with thoracic sarcoidosis.
  • One patient had metastatic melanoma and was undergoing BRAF/MEK inhibitor treatment; the other had early-stage melanoma without prior treatment.

Findings:

  • In both cases, thoracic lesions initially appeared metastatic, but biopsies confirmed granulomatous disease (sarcoidosis).
  • Drug-induced sarcoidosis (immune checkpoint inhibitors, BRAF/MEK inhibitors) appears more common in real-world settings than in clinical trials.

Implications:

  • Sarcoidosis can present as a diagnostic challenge, mimicking melanoma metastasis, particularly in the mediastinum.
  • Biopsies are essential for accurate diagnosis, distinguishing sarcoidosis from metastatic melanoma before commencing antineoplastic treatment.

Related Concept Videos